At a glance
ClinicalIndex Comparison Record- ✓Age 18 years or older
- ✓Diagnosis of hairy cell leukemia confirmed by bone marrow examination
- ✓Relapsed HCL allowed with no more than one prior therapy
- ✓Women of childbearing potential must use contraception during study
- ✕Unable or unwilling to sign consent form
- ✕Known HIV, hepatitis B, or hepatitis C infection
- ✕Presence of active infection
- ✕CNS metastases present
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed by Rituximab in Hairy Cell Leukemia
In Brief
A Phase 2 clinical trial evaluating Cladribine, Laboratory Biomarker Analysis, and 1 other intervention for Hairy Cell Leukemia and Recurrent Hairy Cell Leukemia. Currently recruiting, targeting 150 participants across 1 site.
Detailed Summary
This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.
Study Details
Timeline
Arms & Interventions
Patients receive cladribine IV over 2 hours QD on days 1-5 and rituximab IV once weekly for 8 weeks beginning on day 28 in the absence of disease progression or unacceptable toxicity.
Interventions
Given IV
Correlative studies
Given IV